Delivery of plasmid DNA encoding bone morphogenetic protein-2 with a biodegradable branched polycationic polymer in a critical-size rat cranial defect model.
This study investigated the delivery of plasmid DNA (pDNA) encoding bone morphogenetic protein-2 in the form of polyplexes with a biodegradable branched triacrylate/amine polycationic polymer (TAPP) that were complexed with gelatin microparticles (GMPs) loaded within a porous tissue engineering scaffold. More specifically, the study investigated the interplay between TAPP degradation, gelatin degradation, pDNA release, and bone formation in a critical-size rat cranial defect model. The pDNA release kinetics in vitro were not affected by the crosslinking density of the GMPs but depended, rather, on the degradation rates of the TAPPs. Besides the initial release of polyplexes not bound to the GMPs and the minimal release of polyplexes through diffusion or dissociation from the GMPs, the pDNA was likely released as naked pDNA or as part of an incomplete polyplex, after the degradation of fragments of the polycationic polymer. After 30 days, significantly higher amounts of pDNA were released (93%-98%) from composite scaffolds containing naked pDNA or pDNA complexed with P-AEPZ (synthesized with 1-[2-aminoethyl]piperazine, a faster degrading TAPP) compared with those containing pDNA complexed with P-DED (synthesized with N,N-dimethylethylenediamine, a slower degrading TAPP) (74%-82%). Composite scaffolds containing GMPs complexed with TAPP/pDNA polyplexes did not result in enhanced bone formation, as analyzed by microcomputed tomography and histology, in a critical-size rat cranial defect at 12 weeks postimplantation compared with those loaded with naked pDNA. The results demonstrate that polycationic polymers with a slow degradation rate can prolong the release of pDNA from the composite scaffolds and suggest that a gene delivery system comprising biodegradable polycationic polymers should be designed to release the pDNA in an intact polyplex form.
Department of Bioengineering, Rice University, Houston, TX 77251-1892, USA.
Sue Anne
SA
Chew
James D
JD
Kretlow
Patrick P
PP
Spicer
Austin W
AW
Edwards
L Scott
LS
Baggett
Yasuhiko
Y
Tabata
F Kurtis
FK
Kasper
Antonios G
AG
Mikos
D000818:Animals; D001673:Biodegradation, Environmental / Q000187:drug effects; D055396:Bone Morphogenetic Protein 2 / Q000494:pharmacology*; D016923:Cell Death / Q000187:drug effects; D004247:DNA / Q000378:metabolism*; D004195:Disease Models, Animal; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D018014:Gene Transfer Techniques; D006801:Humans; D007700:Kinetics; D010012:Osteogenesis / Q000187:drug effects; D010957:Plasmids / Q000378:metabolism*; D011073:Polyamines / Q000494:pharmacology*; D000071228:Polyelectrolytes; D011108:Polymers / Q000494:pharmacology*; D016062:Porosity / Q000187:drug effects; D051381:Rats; D011916:Rats, Inbred F344; D012886:Skull / Q000000981:diagnostic imaging / Q000187:drug effects / Q000473:pathology*; D054457:Tissue Scaffolds / Q000737:chemistry; D014162:Transfection; D055114:X-Ray Microtomography
D055396:Bone Morphogenetic Protein 2; D004247:DNA; D011073:Polyamines; D000071228:Polyelectrolytes; D011108:Polymers